$PGNX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in PROGENICS PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in PROGENICS PHARMACEUTICALS INC. Get notifications about new insider transactions in PROGENICS PHARMACEUTICALS INC for free.
Page: < prev 1 ... 3 4 5 6 7 8 9 10 11 ... 13 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 03 2007 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | A | 22.11 | 636 | 14,062 | 636 | |
| Oct 03 2007 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | M | 19.03 | 748 | 14,234 | 0 | |
| Oct 03 2007 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Payment of Exercise | F | 22.39 | 681 | 15,248 | 24,877 | 25.6 K to 24.9 K (-2.66 %) |
| Oct 03 2007 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Buy | M | 19.03 | 748 | 14,234 | 25,558 | 24.8 K to 25.6 K (+3.01 %) |
| Oct 03 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 12,000 | 63,960 | 15,000 | |
| Oct 03 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 19.03 | 1,995 | 37,965 | 0 | |
| Oct 03 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Payment of Exercise | F | 22.39 | 1,816 | 40,660 | 695,148 | 697 K to 695.1 K (-0.26 %) |
| Oct 03 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 19.03 | 1,995 | 37,965 | 696,964 | 695 K to 697 K (+0.29 %) |
| Oct 03 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 22.03 | 12,000 | 264,312 | 694,969 | 707 K to 695 K (-1.70 %) |
| Oct 03 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 12,000 | 63,960 | 706,969 | 695 K to 707 K (+1.73 %) |
| Sep 19 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 12,000 | 63,960 | 27,000 | |
| Sep 19 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 23.39 | 12,000 | 280,728 | 694,969 | 707 K to 695 K (-1.70 %) |
| Sep 19 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 12,000 | 63,960 | 706,969 | 695 K to 707 K (+1.73 %) |
| Sep 06 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 12,000 | 63,960 | 39,000 | |
| Sep 06 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 23.77 | 12,000 | 285,180 | 694,969 | 707 K to 695 K (-1.70 %) |
| Sep 06 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 12,000 | 63,960 | 706,969 | 695 K to 707 K (+1.73 %) |
| Aug 16 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 17.19 | 1,500 | 25,785 | 0 | |
| Aug 16 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 13.63 | 500 | 6,813 | 0 | |
| Aug 16 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | S | 22.85 | 500 | 11,425 | 36,209 | 36.7 K to 36.2 K (-1.36 %) |
| Aug 16 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 13.63 | 500 | 6,813 | 36,709 | 36.2 K to 36.7 K (+1.38 %) |
| Aug 16 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | S | 22.92 | 1,500 | 34,374 | 36,209 | 37.7 K to 36.2 K (-3.98 %) |
| Aug 16 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 17.19 | 1,500 | 25,785 | 37,709 | 36.2 K to 37.7 K (+4.14 %) |
| Aug 16 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 12,000 | 63,960 | 51,000 | |
| Aug 16 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 23.16 | 12,000 | 277,860 | 694,969 | 707 K to 695 K (-1.70 %) |
| Aug 16 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 12,000 | 63,960 | 706,969 | 695 K to 707 K (+1.73 %) |
| Aug 02 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 12,000 | 63,960 | 63,000 | |
| Aug 02 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 21.23 | 12,000 | 254,784 | 694,969 | 707 K to 695 K (-1.70 %) |
| Aug 02 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 12,000 | 63,960 | 706,969 | 695 K to 707 K (+1.73 %) |
| Jul 18 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 17.19 | 1,500 | 25,785 | 1,500 | |
| Jul 18 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 13.63 | 500 | 6,813 | 500 | |
| Jul 18 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | S | 21.36 | 500 | 10,680 | 36,209 | 36.7 K to 36.2 K (-1.36 %) |
| Jul 18 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 13.63 | 500 | 6,813 | 36,709 | 36.2 K to 36.7 K (+1.38 %) |
| Jul 18 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | S | 21.66 | 1,500 | 32,489 | 36,209 | 37.7 K to 36.2 K (-3.98 %) |
| Jul 18 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 17.19 | 1,500 | 25,785 | 37,709 | 36.2 K to 37.7 K (+4.14 %) |
| Jul 18 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 12,000 | 63,960 | 75,000 | |
| Jul 18 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 21.46 | 12,000 | 257,472 | 694,969 | 707 K to 695 K (-1.70 %) |
| Jul 18 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 12,000 | 63,960 | 706,969 | 695 K to 707 K (+1.73 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | A | 22.01 | 10,000 | 220,100 | 10,000 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Option Exercise | A | 22.01 | 10,000 | 220,100 | 10,000 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Option Exercise | A | 11.08 | 1,250 | 13,850 | 1,250 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | JACOBSON PAUL F | Director | Option Exercise | A | 22.01 | 37,500 | 825,375 | 37,500 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | GOFF STEPHEN P | Director | Option Exercise | A | 22.01 | 10,000 | 220,100 | 10,000 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | DALTON MARK F | Director | Option Exercise | A | 22.01 | 10,000 | 220,100 | 10,000 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | BRINER KURT W | Director | Option Exercise | A | 22.01 | 37,500 | 825,375 | 37,500 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Option Exercise | A | 22.01 | 7,000 | 154,070 | 7,000 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Option Exercise | A | 21.57 | 406 | 8,757 | 406 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Option Exercise | M | 18.71 | 1,546 | 28,926 | 0 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Payment of Exercise | F | 22.01 | 1,407 | 30,968 | 32,664 | 34.1 K to 32.7 K (-4.13 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Buy | M | 18.71 | 1,546 | 28,926 | 34,071 | 32.5 K to 34.1 K (+4.75 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Grant | A | 0.00 | 9,333 | 0 | 32,525 | 23.2 K to 32.5 K (+40.24 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | BAKER CHARLES A | Director | Option Exercise | A | 22.01 | 10,000 | 220,100 | 10,000 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Option Exercise | A | 22.01 | 10,000 | 220,100 | 10,000 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Option Exercise | A | 21.57 | 753 | 16,242 | 753 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Option Exercise | M | 18.71 | 852 | 15,941 | 0 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Payment of Exercise | F | 22.01 | 775 | 17,058 | 29,426 | 30.2 K to 29.4 K (-2.57 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Buy | M | 18.71 | 852 | 15,941 | 30,201 | 29.3 K to 30.2 K (+2.90 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Grant | A | 0.00 | 13,333 | 0 | 29,349 | 16 K to 29.3 K (+83.25 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | A | 22.01 | 7,000 | 154,070 | 7,000 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | A | 21.57 | 493 | 10,634 | 493 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 18.71 | 545 | 10,197 | 0 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Payment of Exercise | F | 22.01 | 496 | 10,917 | 36,209 | 36.7 K to 36.2 K (-1.35 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 18.71 | 545 | 10,197 | 36,705 | 36.2 K to 36.7 K (+1.51 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Grant | A | 0.00 | 9,333 | 0 | 36,160 | 26.8 K to 36.2 K (+34.79 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | A | 22.01 | 7,000 | 154,070 | 7,000 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | A | 21.57 | 695 | 14,991 | 695 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | M | 18.71 | 2,156 | 40,339 | 0 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Payment of Exercise | F | 22.01 | 1,962 | 43,184 | 35,608 | 37.6 K to 35.6 K (-5.22 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Buy | M | 18.71 | 2,156 | 40,339 | 37,570 | 35.4 K to 37.6 K (+6.09 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Grant | A | 0.00 | 9,333 | 0 | 35,414 | 26.1 K to 35.4 K (+35.78 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | A | 22.01 | 10,000 | 220,100 | 10,000 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | A | 21.57 | 493 | 10,634 | 493 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Grant | A | 0.00 | 13,333 | 0 | 33,124 | 19.8 K to 33.1 K (+67.37 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | A | 22.01 | 10,000 | 220,100 | 10,000 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | A | 21.57 | 652 | 14,064 | 652 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | M | 18.71 | 3,451 | 64,568 | 0 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Payment of Exercise | F | 22.01 | 3,140 | 69,111 | 24,760 | 27.9 K to 24.8 K (-11.25 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Buy | M | 18.71 | 3,451 | 64,568 | 27,900 | 24.4 K to 27.9 K (+14.12 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Grant | A | 0.00 | 13,333 | 0 | 24,398 | 11.1 K to 24.4 K (+120.50 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | A | 22.01 | 112,500 | 2,476,125 | 112,500 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 12,000 | 63,960 | 87,000 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 18.71 | 1,986 | 37,158 | 0 | |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 21.68 | 12,000 | 260,112 | 694,969 | 707 K to 695 K (-1.70 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 12,000 | 63,960 | 706,969 | 695 K to 707 K (+1.73 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Grant | A | 0.00 | 37,500 | 0 | 694,969 | 657.5 K to 695 K (+5.70 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Payment of Exercise | F | 22.01 | 1,807 | 39,772 | 657,469 | 659.3 K to 657.5 K (-0.27 %) |
| Jul 05 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 18.71 | 1,986 | 37,158 | 659,276 | 657.3 K to 659.3 K (+0.30 %) |
| Jun 26 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Sell | D | 22.82 | 200 | 4,564 | 15,965 | 16.2 K to 16 K (-1.24 %) |
| Jun 26 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Sell | D | 22.78 | 100 | 2,278 | 16,165 | 16.3 K to 16.2 K (-0.61 %) |
| Jun 26 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Sell | D | 22.77 | 225 | 5,123 | 16,265 | 16.5 K to 16.3 K (-1.36 %) |
| Jun 26 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Sell | D | 22.76 | 300 | 6,828 | 16,490 | 16.8 K to 16.5 K (-1.79 %) |
| Jun 26 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Sell | D | 22.62 | 200 | 4,524 | 16,790 | 17 K to 16.8 K (-1.18 %) |
| Jun 26 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Sell | D | 22.51 | 400 | 9,004 | 16,990 | 17.4 K to 17 K (-2.30 %) |
| Jun 26 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Sell | D | 22.46 | 1,075 | 24,145 | 17,390 | 18.5 K to 17.4 K (-5.82 %) |
| Jun 25 2007 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Sell | D | 22.46 | 900 | 20,214 | 26,030 | 26.9 K to 26 K (-3.34 %) |
| Jun 25 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | D | 22.65 | 2,150 | 48,689 | 26,776 | 28.9 K to 26.8 K (-7.43 %) |
| Jun 21 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Sell | D | 22.83 | 3,000 | 68,490 | 19,791 | 22.8 K to 19.8 K (-13.16 %) |
| Jun 21 2007 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Sell | D | 22.83 | 1,000 | 22,829 | 23,141 | 24.1 K to 23.1 K (-4.14 %) |
| Jun 18 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 17.19 | 1,500 | 25,785 | 3,000 | |
| Jun 18 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 13.63 | 500 | 6,813 | 1,000 | |
| Jun 18 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | S | 22.04 | 500 | 11,020 | 28,926 | 29.4 K to 28.9 K (-1.70 %) |
| Jun 18 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 13.63 | 500 | 6,813 | 29,426 | 28.9 K to 29.4 K (+1.73 %) |
| Jun 18 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | S | 22.02 | 1,500 | 33,023 | 28,926 | 30.4 K to 28.9 K (-4.93 %) |
| Jun 18 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 17.19 | 1,500 | 25,785 | 30,426 | 28.9 K to 30.4 K (+5.19 %) |
| Jun 04 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 12,000 | 63,960 | 99,000 | |
| Jun 04 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 21.75 | 12,000 | 261,012 | 657,290 | 669.3 K to 657.3 K (-1.79 %) |
| Jun 04 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 12,000 | 63,960 | 669,290 | 657.3 K to 669.3 K (+1.83 %) |
| May 16 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 17.19 | 1,500 | 25,785 | 4,500 | |
| May 16 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 13.63 | 500 | 6,813 | 1,500 | |
| May 16 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | S | 21.90 | 500 | 10,948 | 28,926 | 29.4 K to 28.9 K (-1.70 %) |
| May 16 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 13.63 | 500 | 6,813 | 29,426 | 28.9 K to 29.4 K (+1.73 %) |
| May 16 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | S | 21.91 | 1,500 | 32,864 | 28,926 | 30.4 K to 28.9 K (-4.93 %) |
| May 16 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 17.19 | 1,500 | 25,785 | 30,426 | 28.9 K to 30.4 K (+5.19 %) |
| May 16 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 12,000 | 63,960 | 111,000 | |
| May 16 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 21.90 | 12,000 | 262,800 | 657,290 | 669.3 K to 657.3 K (-1.79 %) |
| May 16 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 12,000 | 63,960 | 669,290 | 657.3 K to 669.3 K (+1.83 %) |
| May 03 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 12,000 | 63,960 | 123,000 | |
| May 03 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 25.61 | 12,000 | 307,356 | 657,290 | 669.3 K to 657.3 K (-1.79 %) |
| May 03 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 12,000 | 63,960 | 669,290 | 657.3 K to 669.3 K (+1.83 %) |
| Apr 17 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | M | 5.33 | 12,000 | 63,960 | 135,000 | |
| Apr 17 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Sell | S | 26.80 | 12,000 | 321,588 | 657,290 | 669.3 K to 657.3 K (-1.79 %) |
| Apr 17 2007 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Buy | M | 5.33 | 12,000 | 63,960 | 669,290 | 657.3 K to 669.3 K (+1.83 %) |
| Apr 24 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Sell | D | 0.00 | 5,000 | 0 | 18,187 | 23.2 K to 18.2 K (-21.56 %) |
| Apr 18 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 17.19 | 1,500 | 25,785 | 6,000 | |
| Apr 18 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 13.63 | 500 | 6,813 | 2,000 | |
| Apr 18 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | S | 27.06 | 500 | 13,530 | 28,926 | 29.4 K to 28.9 K (-1.70 %) |
| Apr 18 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 13.63 | 500 | 6,813 | 29,426 | 28.9 K to 29.4 K (+1.73 %) |
| Apr 18 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | S | 26.81 | 1,500 | 40,221 | 28,926 | 30.4 K to 28.9 K (-4.93 %) |
| Apr 18 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 17.19 | 1,500 | 25,785 | 30,426 | 28.9 K to 30.4 K (+5.19 %) |
| Apr 18 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | D | 0.00 | 5,000 | 0 | 28,676 | 33.7 K to 28.7 K (-14.85 %) |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Option Exercise | A | 20.13 | 414 | 8,334 | 414 | |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Option Exercise | M | 20.13 | 394 | 7,931 | 0 | |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Payment of Exercise | F | 24.10 | 355 | 8,556 | 24,141 | 24.5 K to 24.1 K (-1.45 %) |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Buy | M | 20.13 | 394 | 7,931 | 24,496 | 24.1 K to 24.5 K (+1.63 %) |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Option Exercise | A | 20.13 | 776 | 15,621 | 776 | |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Option Exercise | M | 20.13 | 2,298 | 46,259 | 0 | |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Payment of Exercise | F | 24.10 | 2,071 | 49,911 | 23,465 | 25.5 K to 23.5 K (-8.11 %) |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | Kremer Alton B | VP, Clinical Resear ... | Buy | M | 20.13 | 2,298 | 46,259 | 25,536 | 23.2 K to 25.5 K (+9.89 %) |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | A | 20.13 | 497 | 10,005 | 497 | |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | M | 20.13 | 466 | 9,381 | 0 | |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Payment of Exercise | F | 24.10 | 420 | 10,122 | 22,791 | 23.2 K to 22.8 K (-1.81 %) |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Buy | M | 20.13 | 466 | 9,381 | 23,211 | 22.7 K to 23.2 K (+2.05 %) |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | A | 20.13 | 497 | 10,005 | 497 | |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 20.13 | 2,018 | 40,622 | 0 | |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Payment of Exercise | F | 24.10 | 1,819 | 43,838 | 33,926 | 35.7 K to 33.9 K (-5.09 %) |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 20.13 | 2,018 | 40,622 | 35,745 | 33.7 K to 35.7 K (+5.98 %) |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | A | 20.13 | 722 | 14,534 | 722 | |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | M | 20.13 | 699 | 14,071 | 0 | |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Payment of Exercise | F | 24.10 | 630 | 15,183 | 26,930 | 27.6 K to 26.9 K (-2.29 %) |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Buy | M | 20.13 | 699 | 14,071 | 27,560 | 26.9 K to 27.6 K (+2.60 %) |
| Apr 04 2007 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | A | 20.13 | 660 | 13,286 | 660 |